Raav2tyf-cb-hrs1
WebSummary. This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X … WebIntravitreal Delivery of rAAV2tYF-CB-hRS1 Vector for Gene Augmentation Therapy in X-linked Retinoschisis - 1 Year Clinical Results. (PubMed, Ophthalmol Retina) - "Gene …
Raav2tyf-cb-hrs1
Did you know?
WebPurpose: To evaluate the safety and efficacy of rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus vector expressing retinoschisin (RS1), in individuals with retinal disease … WebN2 - Purpose: To evaluate the safety and efficacy of rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus vector expressing retinoschisin (RS1), in individuals with retinal …
WebMay 1, 2015 · rAAV2tYF-CB-hRS1 in Nonhuman Primates Guo-jie Y e, 1 Ewa Budzynski, 2 Peter Sonnentag, 2 Paul Miller, 3 Alok K. Sharma, 2 James Hoeve, 3 Kenneth S. Latimer, 2 … Webresidual level of rHSV in a single dose of rAAV2tYF-CB-hRS1 can be made. The total input quantity of rHSV infectious particles in a 25 L production batch is 3 x 10^11 pfu and a 13.29 log10 reduction of this value is 1.54 x 10^-2 pfu remaining in the final formulated bulk product which has a volume of 100 mL. The volume of the highest
WebNov 18, 2024 · Ye GJ, Budzynski E, Sonnentag P et al. Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin. Hum. Gene Ther. Clin. Dev. 2015; 26(3), 165–176. WebWe report here results of a study evaluating the safety and biodistribution of rAAV2tYF-CB-hRS1 in normal cynomolgus macaques. Three groups of male animals (n = 6 per group) …
WebAug 25, 2015 · We report here results of a study evaluating the safety and biodistribution of rAAV2tYF-CB-hRS1 in RS1-deficient mice. Three groups of male RS1-deficient mice received an intravitreal injection in one eye of either vehicle, or rAAV2tYF-CB-hRS1 at one of two dose levels (1 × 10 9 or 4 × 10 9 vg/eye) and were sacrificed 30 or 90 days later.
WebJun 30, 2024 · Methods: Participants received an intravitreal (IVT) injection of rAAV2tYF-CB-hRS1, at one of three dose levels, in the poorer-seeing eye and were followed for a … michaelson lawyers \\u0026 associatesWebMay 1, 2015 · Histological examination showed mononuclear cell infiltrates that were more prevalent at the higher dose level and RS1 expression in the retinal ganglion cell ring was … the net magazineWebMar 4, 2024 · March 4, 2024. Biogen has agreed to acquire Nightstar Therapeutics for approximately $877 million, the companies said today, in a deal that replenishes the buyer’s ophthalmology drug pipeline ... michaelson musicWebSep 1, 2015 · The rAAV2tYF-CB-hRS1 vector was produced using a recombinant herpes simplex virus (rHSV) complementation system in suspension-cultured baby hamster … michaelson owatonna mnWebMay 18, 2015 · Results demonstrated that intravitreal injection of rAAV2tYF-CB-hRS1 was well tolerated with minimal ocular inflammatory cells detected by histopathology. RS1 expression, measured by immunohistochemistry, was associated with decreased severity of splitting and disorganization of the inner nuclear layer of the retina at the higher dose … the net magazine medwayWebMay 1, 2015 · rAAV2tYF-CB-hRS1 in Nonhuman Primates Guo-jie Y e, 1 Ewa Budzynski, 2 Peter Sonnentag, 2 Paul Miller, 3 Alok K. Sharma, 2 James Hoeve, 3 Kenneth S. Latimer, 2 Kellie Howard, 4 michaelson road bridgeWebApr 26, 2024 · (rAAV2tYF-GRK1-RPGR) Applied Genetic Technologies Corp NCT03316560 Choroideremia REP1 I/II 14 Oct-2011 Oct-2024 rAAV2.REP1 University of Oxford NCT01461213 [14] ... I/II 27 May-2015 Oct-2024 rAAV2tYF-CB-hRS1 Applied Genetic Technologies Corp NCT02416622 RPE65: Retinal pigmented epithelium-specific protein … the net loft portmellon